APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibacterial (Drug) Resistance

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032

22 December 2025212 pages

Choose your research edition.

Industry ResearchAntibacterial (Drug) Resistance Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Antibacterial (Drug) Resistance market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antibacterial (Drug) Resistance is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antibacterial (Drug) Resistance is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antibacterial (Drug) Resistance is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antibacterial (Drug) Resistance is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antibacterial (Drug) Resistance include Merck, Pfizer, GSK, VenatoRx Pharmaceuticals, PENDOPHARM, Osel, Novexel, NanoSafe Coatings and Nabriva Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antibacterial (Drug) Resistance, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antibacterial (Drug) Resistance, also provides the sales of main regions and countries. Of the upcoming market potential for Antibacterial (Drug) Resistance, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibacterial (Drug) Resistance sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antibacterial (Drug) Resistance market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antibacterial (Drug) Resistance sales, projected growth trends, production technology, application and end-user industry.

Antibacterial (Drug) Resistance Segment by Company

Merck

Pfizer

GSK

VenatoRx Pharmaceuticals

PENDOPHARM

Osel

Novexel

NanoSafe Coatings

Nabriva Therapeutics

Morphochem

Microbecide

Melinta Therapeutics

Lyndra

Isis Pharmaceuticals

InterMune

Evolva Holding

Demuris

ContraFect

Cerexa

Aventis Pharma

Austell Laboratories

Assembly Biosciences

Arpida

ANTABIO

Allergan

Acino Holdings

Achaogen

Absynth Biologics

Abbott Laboratories

AAIPharma Services

Antibacterial (Drug) Resistance Segment by Type

Ceftolozane-Tazobactam (Zerbaxa)

Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

Ceftaroline Fosamil (Teflaro/ Zinforo)

Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Telavancin (Vibativ)

Tedizolid Phosphate (Sivextro)

PHASE III DRUGS

Dalbavancin (Dalvance/ Xydalba)

Oritavancin (Orbactiv/ Nuvocid)

Fidaxomicin (Dificid / Dificlir)

Antibacterial (Drug) Resistance Segment by Application

Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Blood Stream Infections (BSI)

Community Acquired Bacterial Pneumonia (CABP)

Clostridium Difficile Infections (CDI)

Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Complicated Urinary Tract Infection (CUTI)

Complicated Intra-Abdominal Infections (CIAI)

Antibacterial (Drug) Resistance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibacterial (Drug) Resistance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibacterial (Drug) Resistance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibacterial (Drug) Resistance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antibacterial (Drug) Resistance in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibacterial (Drug) Resistance sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ceftolozane-Tazobactam (Zerbaxa) Major Manufacturers Table 3. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Major Manufacturers Table 4. Ceftaroline Fosamil (Teflaro/ Zinforo) Major Manufacturers Table 5. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Major Manufacturers Table 6. Telavancin (Vibativ) Major Manufacturers Table 7. Tedizolid Phosphate (Sivextro) Major Manufacturers Table 8. PHASE III DRUGS Major Manufacturers Table 9. Dalbavancin (Dalvance/ Xydalba) Major Manufacturers Table 10. Oritavancin (Orbactiv/ Nuvocid) Major Manufacturers Table 11. Fidaxomicin (Dificid / Dificlir) Major Manufacturers Table 12. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 13. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Major Manufacturers Table 14. Blood Stream Infections (BSI) Major Manufacturers Table 15. Community Acquired Bacterial Pneumonia (CABP) Major Manufacturers Table 16. Clostridium Difficile Infections (CDI) Major Manufacturers Table 17. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Major Manufacturers Table 18. Complicated Urinary Tract Infection (CUTI) Major Manufacturers Table 19. Complicated Intra-Abdominal Infections (CIAI) Major Manufacturers Table 20. Antibacterial (Drug) Resistance Industry Trends Table 21. Antibacterial (Drug) Resistance Industry Drivers Table 22. Antibacterial (Drug) Resistance Industry Opportunities and Challenges Table 23. Antibacterial (Drug) Resistance Industry Restraints Table 24. Global Antibacterial (Drug) Resistance Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antibacterial (Drug) Resistance Revenue by Region (2021-2026) & (US$ Million) Table 26. Global Antibacterial (Drug) Resistance Revenue by Region (2027-2032) & (US$ Million) Table 27. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2026) Table 28. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2027-2032) Table 29. Global Antibacterial (Drug) Resistance Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 30. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (k units) Table 31. Global Antibacterial (Drug) Resistance Sales by Region (2027-2032) & (k units) Table 32. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2026) Table 33. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2027-2032) Table 34. Global Antibacterial (Drug) Resistance Revenue by Manufacturers (US$ Million) & (2021-2026) Table 35. Global Antibacterial (Drug) Resistance Revenue Market Share by Manufacturers (2021-2026) Table 36. Global Antibacterial (Drug) Resistance Sales by Manufacturers (US$ Million) & (2021-2026) Table 37. Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2021-2026) Table 38. Global Antibacterial (Drug) Resistance Sales Price (US$/unit) of Manufacturers (2021-2026) Table 39. Global Antibacterial (Drug) Resistance Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 40. Global Antibacterial (Drug) Resistance Key Manufacturers Manufacturing Sites & Headquarters Table 41. Global Antibacterial (Drug) Resistance Manufacturers, Product Type & Application Table 42. Global Antibacterial (Drug) Resistance Manufacturers' Establishment Date Table 43. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 44. Global Antibacterial (Drug) Resistance by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global Antibacterial (Drug) Resistance Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 47. Global Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 48. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2026) Table 49. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2027-2032) Table 50. Global Antibacterial (Drug) Resistance Sales by Type 2021 VS 2025 VS 2032 (k units) Table 51. Global Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 52. Global Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 53. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2026) Table 54. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2027-2032) Table 55. Global Antibacterial (Drug) Resistance Price by Type (2021-2026) & (US$/unit) Table 56. Global Antibacterial (Drug) Resistance Price by Type (2027-2032) & (US$/unit) Table 57. Global Antibacterial (Drug) Resistance Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 59. Global Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 60. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2026) Table 61. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2027-2032) Table 62. Global Antibacterial (Drug) Resistance Sales by Application 2021 VS 2025 VS 2032 (k units) Table 63. Global Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 64. Global Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 65. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2026) Table 66. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2027-2032) Table 67. Global Antibacterial (Drug) Resistance Price by Application (2021-2026) & (US$/unit) Table 68. Global Antibacterial (Drug) Resistance Price by Application (2027-2032) & (US$/unit) Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Merck Antibacterial (Drug) Resistance Product Portfolio Table 73. Merck Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Pfizer Antibacterial (Drug) Resistance Product Portfolio Table 78. Pfizer Recent Development Table 79. GSK Company Information Table 80. GSK Business Overview Table 81. GSK Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. GSK Antibacterial (Drug) Resistance Product Portfolio Table 83. GSK Recent Development Table 84. VenatoRx Pharmaceuticals Company Information Table 85. VenatoRx Pharmaceuticals Business Overview Table 86. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 88. VenatoRx Pharmaceuticals Recent Development Table 89. PENDOPHARM Company Information Table 90. PENDOPHARM Business Overview Table 91. PENDOPHARM Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio Table 93. PENDOPHARM Recent Development Table 94. Osel Company Information Table 95. Osel Business Overview Table 96. Osel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Osel Antibacterial (Drug) Resistance Product Portfolio Table 98. Osel Recent Development Table 99. Novexel Company Information Table 100. Novexel Business Overview Table 101. Novexel Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Novexel Antibacterial (Drug) Resistance Product Portfolio Table 103. Novexel Recent Development Table 104. NanoSafe Coatings Company Information Table 105. NanoSafe Coatings Business Overview Table 106. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio Table 108. NanoSafe Coatings Recent Development Table 109. Nabriva Therapeutics Company Information Table 110. Nabriva Therapeutics Business Overview Table 111. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 113. Nabriva Therapeutics Recent Development Table 114. Morphochem Company Information Table 115. Morphochem Business Overview Table 116. Morphochem Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Morphochem Antibacterial (Drug) Resistance Product Portfolio Table 118. Morphochem Recent Development Table 119. Microbecide Company Information Table 120. Microbecide Business Overview Table 121. Microbecide Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Microbecide Antibacterial (Drug) Resistance Product Portfolio Table 123. Microbecide Recent Development Table 124. Melinta Therapeutics Company Information Table 125. Melinta Therapeutics Business Overview Table 126. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 128. Melinta Therapeutics Recent Development Table 129. Lyndra Company Information Table 130. Lyndra Business Overview Table 131. Lyndra Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Lyndra Antibacterial (Drug) Resistance Product Portfolio Table 133. Lyndra Recent Development Table 134. Isis Pharmaceuticals Company Information Table 135. Isis Pharmaceuticals Business Overview Table 136. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 138. Isis Pharmaceuticals Recent Development Table 139. InterMune Company Information Table 140. InterMune Business Overview Table 141. InterMune Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. InterMune Antibacterial (Drug) Resistance Product Portfolio Table 143. InterMune Recent Development Table 144. Evolva Holding Company Information Table 145. Evolva Holding Business Overview Table 146. Evolva Holding Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Evolva Holding Antibacterial (Drug) Resistance Product Portfolio Table 148. Evolva Holding Recent Development Table 149. Demuris Company Information Table 150. Demuris Business Overview Table 151. Demuris Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Demuris Antibacterial (Drug) Resistance Product Portfolio Table 153. Demuris Recent Development Table 154. ContraFect Company Information Table 155. ContraFect Business Overview Table 156. ContraFect Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 157. ContraFect Antibacterial (Drug) Resistance Product Portfolio Table 158. ContraFect Recent Development Table 159. Cerexa Company Information Table 160. Cerexa Business Overview Table 161. Cerexa Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 162. Cerexa Antibacterial (Drug) Resistance Product Portfolio Table 163. Cerexa Recent Development Table 164. Aventis Pharma Company Information Table 165. Aventis Pharma Business Overview Table 166. Aventis Pharma Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 167. Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio Table 168. Aventis Pharma Recent Development Table 169. Austell Laboratories Company Information Table 170. Austell Laboratories Business Overview Table 171. Austell Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 172. Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 173. Austell Laboratories Recent Development Table 174. Assembly Biosciences Company Information Table 175. Assembly Biosciences Business Overview Table 176. Assembly Biosciences Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 177. Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio Table 178. Assembly Biosciences Recent Development Table 179. Arpida Company Information Table 180. Arpida Business Overview Table 181. Arpida Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 182. Arpida Antibacterial (Drug) Resistance Product Portfolio Table 183. Arpida Recent Development Table 184. ANTABIO Company Information Table 185. ANTABIO Business Overview Table 186. ANTABIO Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 187. ANTABIO Antibacterial (Drug) Resistance Product Portfolio Table 188. ANTABIO Recent Development Table 189. Allergan Company Information Table 190. Allergan Business Overview Table 191. Allergan Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 192. Allergan Antibacterial (Drug) Resistance Product Portfolio Table 193. Allergan Recent Development Table 194. Acino Holdings Company Information Table 195. Acino Holdings Business Overview Table 196. Acino Holdings Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 197. Acino Holdings Antibacterial (Drug) Resistance Product Portfolio Table 198. Acino Holdings Recent Development Table 199. Achaogen Company Information Table 200. Achaogen Business Overview Table 201. Achaogen Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 202. Achaogen Antibacterial (Drug) Resistance Product Portfolio Table 203. Achaogen Recent Development Table 204. Absynth Biologics Company Information Table 205. Absynth Biologics Business Overview Table 206. Absynth Biologics Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 207. Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio Table 208. Absynth Biologics Recent Development Table 209. Abbott Laboratories Company Information Table 210. Abbott Laboratories Business Overview Table 211. Abbott Laboratories Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 212. Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 213. Abbott Laboratories Recent Development Table 214. AAIPharma Services Company Information Table 215. AAIPharma Services Business Overview Table 216. AAIPharma Services Antibacterial (Drug) Resistance Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 217. AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio Table 218. AAIPharma Services Recent Development Table 219. North America Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 220. North America Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 221. North America Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 222. North America Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 223. North America Antibacterial (Drug) Resistance Sales Price by Type (2021-2026) & (US$/unit) Table 224. North America Antibacterial (Drug) Resistance Sales Price by Type (2027-2032) & (US$/unit) Table 225. North America Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 226. North America Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 227. North America Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 228. North America Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 229. North America Antibacterial (Drug) Resistance Sales Price by Application (2021-2026) & (US$/unit) Table 230. North America Antibacterial (Drug) Resistance Sales Price by Application (2027-2032) & (US$/unit) Table 231. North America Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 232. North America Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 233. North America Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 234. North America Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 235. North America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 236. North America Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 237. North America Antibacterial (Drug) Resistance Sales Price by Country (2021-2026) & (US$/unit) Table 238. North America Antibacterial (Drug) Resistance Sales Price by Country (2027-2032) & (US$/unit) Table 239. United States Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 240. Canada Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 241. Mexico Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 242. Europe Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 243. Europe Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 244. Europe Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 245. Europe Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 246. Europe Antibacterial (Drug) Resistance Sales Price by Type (2021-2026) & (US$/unit) Table 247. Europe Antibacterial (Drug) Resistance Sales Price by Type (2027-2032) & (US$/unit) Table 248. Europe Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 249. Europe Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 250. Europe Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 251. Europe Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 252. Europe Antibacterial (Drug) Resistance Sales Price by Application (2021-2026) & (US$/unit) Table 253. Europe Antibacterial (Drug) Resistance Sales Price by Application (2027-2032) & (US$/unit) Table 254. Europe Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 255. Europe Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 256. Europe Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 257. Europe Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 258. Europe Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 259. Europe Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 260. Europe Antibacterial (Drug) Resistance Sales Price by Country (2021-2026) & (US$/unit) Table 261. Europe Antibacterial (Drug) Resistance Sales Price by Country (2027-2032) & (US$/unit) Table 262. Germany Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 263. France Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 264. U.K. Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 265. Italy Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 266. Russia Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 267. Spain Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 268. Netherlands Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 269. Switzerland Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 270. Sweden Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 271. Poland Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 272. China Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 273. China Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 274. China Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 275. China Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 276. China Antibacterial (Drug) Resistance Sales Price by Type (2021-2026) & (US$/unit) Table 277. China Antibacterial (Drug) Resistance Sales Price by Type (2027-2032) & (US$/unit) Table 278. China Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 279. China Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 280. China Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 281. China Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 282. China Antibacterial (Drug) Resistance Sales Price by Application (2021-2026) & (US$/unit) Table 283. China Antibacterial (Drug) Resistance Sales Price by Application (2027-2032) & (US$/unit) Table 284. Asia Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 285. Asia Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 286. Asia Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 287. Asia Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 288. Asia Antibacterial (Drug) Resistance Sales Price by Type (2021-2026) & (US$/unit) Table 289. Asia Antibacterial (Drug) Resistance Sales Price by Type (2027-2032) & (US$/unit) Table 290. Asia Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 291. Asia Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 292. Asia Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 293. Asia Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 294. Asia Antibacterial (Drug) Resistance Sales Price by Application (2021-2026) & (US$/unit) Table 295. Asia Antibacterial (Drug) Resistance Sales Price by Application (2027-2032) & (US$/unit) Table 296. Asia Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 297. Asia Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 298. Asia Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 299. Asia Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 300. Asia Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 301. Asia Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 302. Asia Antibacterial (Drug) Resistance Sales Price by Country (2021-2026) & (US$/unit) Table 303. Asia Antibacterial (Drug) Resistance Sales Price by Country (2027-2032) & (US$/unit) Table 304. Japan Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 305. South Korea Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 306. India Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 307. Australia Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 308. Taiwan Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 309. Southeast Asia Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 310. SAMEA Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (US$ Million) Table 311. SAMEA Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (US$ Million) Table 312. SAMEA Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 313. SAMEA Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 314. SAMEA Antibacterial (Drug) Resistance Sales Price by Type (2021-2026) & (US$/unit) Table 315. SAMEA Antibacterial (Drug) Resistance Sales Price by Type (2027-2032) & (US$/unit) Table 316. SAMEA Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (US$ Million) Table 317. SAMEA Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (US$ Million) Table 318. SAMEA Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 319. SAMEA Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 320. SAMEA Antibacterial (Drug) Resistance Sales Price by Application (2021-2026) & (US$/unit) Table 321. SAMEA Antibacterial (Drug) Resistance Sales Price by Application (2027-2032) & (US$/unit) Table 322. SAMEA Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 323. SAMEA Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 324. SAMEA Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 325. SAMEA Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 326. SAMEA Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 327. SAMEA Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 328. SAMEA Antibacterial (Drug) Resistance Sales Price by Country (2021-2026) & (US$/unit) Table 329. SAMEA Antibacterial (Drug) Resistance Sales Price by Country (2027-2032) & (US$/unit) Table 330. Brazil Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 331. Argentina Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 332. Chile Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 333. Colombia Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 334. Peru Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 335. Saudi Arabia Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 336. Israel Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 337. UAE Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 338. Turkey Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 339. Iran Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 340. Egypt Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Table 341. Key Raw Materials Table 342. Raw Materials Key Suppliers Table 343. Antibacterial (Drug) Resistance Distributors List Table 344. Antibacterial (Drug) Resistance Customers List Table 345. Research Programs/Design for This Report Table 346. Authors List of This Report Table 347. Secondary Sources Table 348. Primary Sources List of Figures Figure 1. Antibacterial (Drug) Resistance Image Figure 2. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibacterial (Drug) Resistance Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ceftolozane-Tazobactam (Zerbaxa) Image Figure 5. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Image Figure 6. Ceftaroline Fosamil (Teflaro/ Zinforo) Image Figure 7. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Image Figure 8. Telavancin (Vibativ) Image Figure 9. Tedizolid Phosphate (Sivextro) Image Figure 10. PHASE III DRUGS Image Figure 11. Dalbavancin (Dalvance/ Xydalba) Image Figure 12. Oritavancin (Orbactiv/ Nuvocid) Image Figure 13. Fidaxomicin (Dificid / Dificlir) Image Figure 14. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Antibacterial (Drug) Resistance Market Size Share 2021 VS 2025 VS 2032 Figure 16. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Image Figure 17. Blood Stream Infections (BSI) Image Figure 18. Community Acquired Bacterial Pneumonia (CABP) Image Figure 19. Clostridium Difficile Infections (CDI) Image Figure 20. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Image Figure 21. Complicated Urinary Tract Infection (CUTI) Image Figure 22. Complicated Intra-Abdominal Infections (CIAI) Image Figure 23. Global Antibacterial (Drug) Resistance Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 24. Global Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Figure 25. Global Antibacterial (Drug) Resistance Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Antibacterial (Drug) Resistance Revenue Market Share by Region: 2025 Versus 2032 Figure 27. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2032) Figure 28. Global Antibacterial (Drug) Resistance Sales (2021-2032) & (k units) Figure 29. Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2032) Figure 31. US & Canada & Mexico Antibacterial (Drug) Resistance Sales YoY (2021-2032) & (k units) Figure 32. Europe Antibacterial (Drug) Resistance Sales YoY (2021-2032) & (k units) Figure 33. China Antibacterial (Drug) Resistance Sales YoY (2021-2032) & (k units) Figure 34. Asia (Excluding China) Antibacterial (Drug) Resistance Sales YoY (2021-2032) & (k units)

Scope & coverage.

Types
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • Telavancin (Vibativ)
  • Tedizolid Phosphate (Sivextro)
  • PHASE III DRUGS
  • Dalbavancin (Dalvance/ Xydalba)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Fidaxomicin (Dificid / Dificlir)
Applications
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
Companies covered
  • Merck
  • Pfizer
  • GSK
  • VenatoRx Pharmaceuticals
  • PENDOPHARM
  • Osel
  • Novexel
  • NanoSafe Coatings
  • Nabriva Therapeutics
  • Morphochem
  • Microbecide
  • Melinta Therapeutics
  • Lyndra
  • Isis Pharmaceuticals
  • InterMune
  • Evolva Holding
  • Demuris
  • ContraFect
  • Cerexa
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • ANTABIO
  • Allergan
  • Acino Holdings
  • Achaogen
  • Absynth Biologics
  • Abbott Laboratories
  • AAIPharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antibacterial (Drug) Resistance Market by Type
  3. 1.2.1 Global Antibacterial (Drug) Resistance Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ceftolozane-Tazobactam (Zerbaxa)
  5. 1.2.3 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  6. 1.2.4 Ceftaroline Fosamil (Teflaro/ Zinforo)
  7. 1.2.5 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  8. 1.2.6 Telavancin (Vibativ)
  9. 1.2.7 Tedizolid Phosphate (Sivextro)
  10. 1.2.8 PHASE III DRUGS
  11. 1.2.9 Dalbavancin (Dalvance/ Xydalba)
  12. 1.2.10 Oritavancin (Orbactiv/ Nuvocid)
  13. 1.2.11 Fidaxomicin (Dificid / Dificlir)
  14. 1.3 Antibacterial (Drug) Resistance Market by Application
  15. 1.3.1 Global Antibacterial (Drug) Resistance Market Size by Application, 2021 VS 2025 VS 2032
  16. 1.3.2 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  17. 1.3.3 Blood Stream Infections (BSI)
  18. 1.3.4 Community Acquired Bacterial Pneumonia (CABP)
  19. 1.3.5 Clostridium Difficile Infections (CDI)
  20. 1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  21. 1.3.7 Complicated Urinary Tract Infection (CUTI)
  22. 1.3.8 Complicated Intra-Abdominal Infections (CIAI)
  23. 1.4 Assumptions and Limitations
  24. 1.5 Study Goals and Objectives
2 Antibacterial (Drug) Resistance Market Dynamics
  1. 2.1 Antibacterial (Drug) Resistance Industry Trends
  2. 2.2 Antibacterial (Drug) Resistance Industry Drivers
  3. 2.3 Antibacterial (Drug) Resistance Industry Opportunities and Challenges
  4. 2.4 Antibacterial (Drug) Resistance Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antibacterial (Drug) Resistance Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antibacterial (Drug) Resistance Revenue by Region
  3. 3.2.1 Global Antibacterial (Drug) Resistance Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antibacterial (Drug) Resistance Revenue by Region (2021-2026)
  5. 3.2.3 Global Antibacterial (Drug) Resistance Revenue by Region (2027-2032)
  6. 3.2.4 Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antibacterial (Drug) Resistance Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antibacterial (Drug) Resistance Sales by Region
  9. 3.4.1 Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antibacterial (Drug) Resistance Sales by Region (2021-2026)
  11. 3.4.3 Global Antibacterial (Drug) Resistance Sales by Region (2027-2032)
  12. 3.4.4 Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antibacterial (Drug) Resistance Revenue by Manufacturers
  2. 4.1.1 Global Antibacterial (Drug) Resistance Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antibacterial (Drug) Resistance Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antibacterial (Drug) Resistance Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antibacterial (Drug) Resistance Sales by Manufacturers
  6. 4.2.1 Global Antibacterial (Drug) Resistance Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antibacterial (Drug) Resistance Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antibacterial (Drug) Resistance Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antibacterial (Drug) Resistance Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antibacterial (Drug) Resistance Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antibacterial (Drug) Resistance Manufacturers, Product Type & Application
  13. 4.7 Global Antibacterial (Drug) Resistance Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antibacterial (Drug) Resistance Market CR5 and HHI
  16. 4.8.2 2025 Antibacterial (Drug) Resistance Tier 1, Tier 2, and Tier 3
5 Antibacterial (Drug) Resistance Market by Type
  1. 5.1 Global Antibacterial (Drug) Resistance Revenue by Type
  2. 5.1.1 Global Antibacterial (Drug) Resistance Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antibacterial (Drug) Resistance Sales by Type
  6. 5.2.1 Global Antibacterial (Drug) Resistance Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibacterial (Drug) Resistance Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antibacterial (Drug) Resistance Price by Type
6 Antibacterial (Drug) Resistance Market by Application
  1. 6.1 Global Antibacterial (Drug) Resistance Revenue by Application
  2. 6.1.1 Global Antibacterial (Drug) Resistance Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antibacterial (Drug) Resistance Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antibacterial (Drug) Resistance Sales by Application
  6. 6.2.1 Global Antibacterial (Drug) Resistance Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antibacterial (Drug) Resistance Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antibacterial (Drug) Resistance Price by Application
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Merck Antibacterial (Drug) Resistance Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 GSK
  14. 7.3.1 GSK Company Information
  15. 7.3.2 GSK Business Overview
  16. 7.3.3 GSK Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 GSK Antibacterial (Drug) Resistance Product Portfolio
  18. 7.3.5 GSK Recent Developments
  19. 7.4 VenatoRx Pharmaceuticals
  20. 7.4.1 VenatoRx Pharmaceuticals Company Information
  21. 7.4.2 VenatoRx Pharmaceuticals Business Overview
  22. 7.4.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  24. 7.4.5 VenatoRx Pharmaceuticals Recent Developments
  25. 7.5 PENDOPHARM
  26. 7.5.1 PENDOPHARM Company Information
  27. 7.5.2 PENDOPHARM Business Overview
  28. 7.5.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
  30. 7.5.5 PENDOPHARM Recent Developments
  31. 7.6 Osel
  32. 7.6.1 Osel Company Information
  33. 7.6.2 Osel Business Overview
  34. 7.6.3 Osel Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Osel Antibacterial (Drug) Resistance Product Portfolio
  36. 7.6.5 Osel Recent Developments
  37. 7.7 Novexel
  38. 7.7.1 Novexel Company Information
  39. 7.7.2 Novexel Business Overview
  40. 7.7.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
  42. 7.7.5 Novexel Recent Developments
  43. 7.8 NanoSafe Coatings
  44. 7.8.1 NanoSafe Coatings Company Information
  45. 7.8.2 NanoSafe Coatings Business Overview
  46. 7.8.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
  48. 7.8.5 NanoSafe Coatings Recent Developments
  49. 7.9 Nabriva Therapeutics
  50. 7.9.1 Nabriva Therapeutics Company Information
  51. 7.9.2 Nabriva Therapeutics Business Overview
  52. 7.9.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  54. 7.9.5 Nabriva Therapeutics Recent Developments
  55. 7.10 Morphochem
  56. 7.10.1 Morphochem Company Information
  57. 7.10.2 Morphochem Business Overview
  58. 7.10.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
  60. 7.10.5 Morphochem Recent Developments
  61. 7.11 Microbecide
  62. 7.11.1 Microbecide Company Information
  63. 7.11.2 Microbecide Business Overview
  64. 7.11.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
  66. 7.11.5 Microbecide Recent Developments
  67. 7.12 Melinta Therapeutics
  68. 7.12.1 Melinta Therapeutics Company Information
  69. 7.12.2 Melinta Therapeutics Business Overview
  70. 7.12.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  72. 7.12.5 Melinta Therapeutics Recent Developments
  73. 7.13 Lyndra
  74. 7.13.1 Lyndra Company Information
  75. 7.13.2 Lyndra Business Overview
  76. 7.13.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
  78. 7.13.5 Lyndra Recent Developments
  79. 7.14 Isis Pharmaceuticals
  80. 7.14.1 Isis Pharmaceuticals Company Information
  81. 7.14.2 Isis Pharmaceuticals Business Overview
  82. 7.14.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  84. 7.14.5 Isis Pharmaceuticals Recent Developments
  85. 7.15 InterMune
  86. 7.15.1 InterMune Company Information
  87. 7.15.2 InterMune Business Overview
  88. 7.15.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
  90. 7.15.5 InterMune Recent Developments
  91. 7.16 Evolva Holding
  92. 7.16.1 Evolva Holding Company Information
  93. 7.16.2 Evolva Holding Business Overview
  94. 7.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
  96. 7.16.5 Evolva Holding Recent Developments
  97. 7.17 Demuris
  98. 7.17.1 Demuris Company Information
  99. 7.17.2 Demuris Business Overview
  100. 7.17.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
  102. 7.17.5 Demuris Recent Developments
  103. 7.18 ContraFect
  104. 7.18.1 ContraFect Company Information
  105. 7.18.2 ContraFect Business Overview
  106. 7.18.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
  108. 7.18.5 ContraFect Recent Developments
  109. 7.19 Cerexa
  110. 7.19.1 Cerexa Company Information
  111. 7.19.2 Cerexa Business Overview
  112. 7.19.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
  114. 7.19.5 Cerexa Recent Developments
  115. 7.20 Aventis Pharma
  116. 7.20.1 Aventis Pharma Company Information
  117. 7.20.2 Aventis Pharma Business Overview
  118. 7.20.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
  120. 7.20.5 Aventis Pharma Recent Developments
  121. 7.21 Austell Laboratories
  122. 7.21.1 Austell Laboratories Company Information
  123. 7.21.2 Austell Laboratories Business Overview
  124. 7.21.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
  126. 7.21.5 Austell Laboratories Recent Developments
  127. 7.22 Assembly Biosciences
  128. 7.22.1 Assembly Biosciences Company Information
  129. 7.22.2 Assembly Biosciences Business Overview
  130. 7.22.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
  132. 7.22.5 Assembly Biosciences Recent Developments
  133. 7.23 Arpida
  134. 7.23.1 Arpida Company Information
  135. 7.23.2 Arpida Business Overview
  136. 7.23.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
  138. 7.23.5 Arpida Recent Developments
  139. 7.24 ANTABIO
  140. 7.24.1 ANTABIO Company Information
  141. 7.24.2 ANTABIO Business Overview
  142. 7.24.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
  144. 7.24.5 ANTABIO Recent Developments
  145. 7.25 Allergan
  146. 7.25.1 Allergan Company Information
  147. 7.25.2 Allergan Business Overview
  148. 7.25.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
  150. 7.25.5 Allergan Recent Developments
  151. 7.26 Acino Holdings
  152. 7.26.1 Acino Holdings Company Information
  153. 7.26.2 Acino Holdings Business Overview
  154. 7.26.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
  156. 7.26.5 Acino Holdings Recent Developments
  157. 7.27 Achaogen
  158. 7.27.1 Achaogen Company Information
  159. 7.27.2 Achaogen Business Overview
  160. 7.27.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
  162. 7.27.5 Achaogen Recent Developments
  163. 7.28 Absynth Biologics
  164. 7.28.1 Absynth Biologics Company Information
  165. 7.28.2 Absynth Biologics Business Overview
  166. 7.28.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  167. 7.28.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
  168. 7.28.5 Absynth Biologics Recent Developments
  169. 7.29 Abbott Laboratories
  170. 7.29.1 Abbott Laboratories Company Information
  171. 7.29.2 Abbott Laboratories Business Overview
  172. 7.29.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  173. 7.29.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
  174. 7.29.5 Abbott Laboratories Recent Developments
  175. 7.30 AAIPharma Services
  176. 7.30.1 AAIPharma Services Company Information
  177. 7.30.2 AAIPharma Services Business Overview
  178. 7.30.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue, Price and Gross Margin (2021-2026)
  179. 7.30.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
  180. 7.30.5 AAIPharma Services Recent Developments
8 North America
  1. 8.1 North America Antibacterial (Drug) Resistance Market Size by Type
  2. 8.1.1 North America Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  3. 8.1.2 North America Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  4. 8.1.3 North America Antibacterial (Drug) Resistance Price by Type (2021-2032)
  5. 8.2 North America Antibacterial (Drug) Resistance Market Size by Application
  6. 8.2.1 North America Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  7. 8.2.2 North America Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  8. 8.2.3 North America Antibacterial (Drug) Resistance Price by Application (2021-2032)
  9. 8.3 North America Antibacterial (Drug) Resistance Market Size by Country
  10. 8.3.1 North America Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antibacterial (Drug) Resistance Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Antibacterial (Drug) Resistance Market Size by Type
  2. 9.1.1 Europe Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  4. 9.1.3 Europe Antibacterial (Drug) Resistance Price by Type (2021-2032)
  5. 9.2 Europe Antibacterial (Drug) Resistance Market Size by Application
  6. 9.2.1 Europe Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  8. 9.2.3 Europe Antibacterial (Drug) Resistance Price by Application (2021-2032)
  9. 9.3 Europe Antibacterial (Drug) Resistance Market Size by Country
  10. 9.3.1 Europe Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antibacterial (Drug) Resistance Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Antibacterial (Drug) Resistance Market Size by Type
  2. 10.1.1 China Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  3. 10.1.2 China Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  4. 10.1.3 China Antibacterial (Drug) Resistance Price by Type (2021-2032)
  5. 10.2 China Antibacterial (Drug) Resistance Market Size by Application
  6. 10.2.1 China Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  7. 10.2.2 China Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  8. 10.2.3 China Antibacterial (Drug) Resistance Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antibacterial (Drug) Resistance Market Size by Type
  2. 11.1.1 Asia Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  4. 11.1.3 Asia Antibacterial (Drug) Resistance Price by Type (2021-2032)
  5. 11.2 Asia Antibacterial (Drug) Resistance Market Size by Application
  6. 11.2.1 Asia Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  8. 11.2.3 Asia Antibacterial (Drug) Resistance Price by Application (2021-2032)
  9. 11.3 Asia Antibacterial (Drug) Resistance Market Size by Country
  10. 11.3.1 Asia Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antibacterial (Drug) Resistance Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antibacterial (Drug) Resistance Market Size by Type
  2. 12.1.1 SAMEA Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antibacterial (Drug) Resistance Price by Type (2021-2032)
  5. 12.2 SAMEA Antibacterial (Drug) Resistance Market Size by Application
  6. 12.2.1 SAMEA Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antibacterial (Drug) Resistance Price by Application (2021-2032)
  9. 12.3 SAMEA Antibacterial (Drug) Resistance Market Size by Country
  10. 12.3.1 SAMEA Antibacterial (Drug) Resistance Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antibacterial (Drug) Resistance Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antibacterial (Drug) Resistance Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antibacterial (Drug) Resistance Value Chain Analysis
  2. 13.1.1 Antibacterial (Drug) Resistance Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antibacterial (Drug) Resistance Production Mode & Process
  6. 13.2 Antibacterial (Drug) Resistance Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antibacterial (Drug) Resistance Distributors
  9. 13.2.3 Antibacterial (Drug) Resistance Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst